Baldi, Bruno Guedes; Radzikowska, Elzbieta; Cottin, Vincent; Dilling, Daniel F; Ataya, Ali; Carvalho, Carlos Roberto Ribeiro De 
; Harari, Sergio; Koslow, Matthew; Grutters, Jan C; Inoue, Yoshikazu
Assuntos: RETRATAÇÃO, SISTEMA RESPIRATÓRIO, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BALDI, Bruno Guedes et al. COVID-19 in lymphangioleiomyomatosis an international study of outcomes and impact of mechanistic target of rapamycin inhibition. [Carta]. Chest. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.chest.2021.12.640. Acesso em: 21 out. 2025. , 2022APA
Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Carvalho, C. R. R. D., et al. (2022). COVID-19 in lymphangioleiomyomatosis an international study of outcomes and impact of mechanistic target of rapamycin inhibition. [Carta]. Chest. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.chest.2021.12.640NLM
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRRD, Harari S, Koslow M, Grutters JC, Inoue Y. COVID-19 in lymphangioleiomyomatosis an international study of outcomes and impact of mechanistic target of rapamycin inhibition. [Carta] [Internet]. Chest. 2022 ; 161( 6): 1589-1593.[citado 2025 out. 21 ] Available from: https://doi.org/10.1016/j.chest.2021.12.640Vancouver
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRRD, Harari S, Koslow M, Grutters JC, Inoue Y. COVID-19 in lymphangioleiomyomatosis an international study of outcomes and impact of mechanistic target of rapamycin inhibition. [Carta] [Internet]. Chest. 2022 ; 161( 6): 1589-1593.[citado 2025 out. 21 ] Available from: https://doi.org/10.1016/j.chest.2021.12.640
